Expanding Global Healthcare Horizons with Multiple Market Authorizations

At Venus Remedies, we believe every new approval is more than just a milestone—it is a step closer to saving lives. Recently, we achieved several important global approvals that bring us closer to patients in need across different parts of the world. These approvals show our growing presence in international markets and reflect the trust placed in our medicines.

Approvals That Make a DifferenceIn Ukraine, we received approvals for Cyclophosphamide (500 mg & 1000 mg) and Doxorubicin (10 mg, 50 mg & 100 mg). Both of these medicines play a key role in treating cancer. With this approval, we are strengthening our oncology portfolio and ensuring patients have access to reliable and effective treatments.

In the United Arab Emirates (UAE), our antibiotic Ceftriaxone (1 gm & 2 gm) has been approved. This is an important step in our ongoing fight against bacterial infections. By adding Ceftriaxone to our offerings in the UAE, we continue our mission to make life-saving antibiotics more widely available.

In Costa Rica, our chemotherapy drug Cytarabine 500 mg received approval. Cytarabine is a widely used cancer treatment, and this approval opens new doors for advanced cancer care in the region. It allows us to reach patients who need trusted and effective cancer therapies.

In Kuwait, our product Cristol (Vincristine 1 mg/1 mL) was granted a fast-track Marketing Authorization (MA). A fast-track approval is special because it shows strong trust from regulators in our quality and innovation. It means our medicine can reach patients more quickly and make an immediate difference in their treatment journey.